• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by CollPlant Biotechnologies Ltd

    1/28/25 4:04:52 PM ET
    $CLGN
    Industrial Specialties
    Health Care
    Get the next $CLGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    CollPlant Biotechnologies Ltd.

    (Name of Issuer)


    Ordinary Shares, par value NIS 1.5 per share

    (Title of Class of Securities)


    19516R107

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    George Walter Loewenbaum
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,140,950.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,140,950.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,140,950.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.96 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Consists of (a) 60,794 shares of the Issuer's ordinary shares underlying American Depository Shares ("ADSs") held by the Walter Loewenbaum Trust, (b) 169,249 ordinary shares underlying ADSs held by the Reporting Person directly, and (c) 910,907 ordinary shares underlying ADSs held by the Reporting Person in an IRA. (2) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    Lillian S. Loewenbaum
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    89,573.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    89,573.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    89,573.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.78 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Consists of (a) 10,000 shares of the Issuer's ordinary shares underlying ADSs held in the Lillian Shaw Loewenbaum Trust, and (b) 79,573 shares of the Issuer's ordinary shares underlying ADSs held by the Reporting Person directly. (2) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    Elizabeth S. Loewenbaum
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    20,688.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    20,688.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    20,688.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.18 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    Lillian S. Loewenbaum Grantor Retained Annuity Trust I
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6,283.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    6,283.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,283.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.05 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    Lillian S. Loewenbaum Grantor Retained Annuity Trust V
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    10,360.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    10,360.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,360.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.09 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    Lillian S. Loewenbaum Grantor Retained Annuity Trust VI
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    16,195.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    16,195.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,195.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.14 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    The Loewenbaum 1992 Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    106,030.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    106,030.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    106,030.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.93 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    The Waterproof Partnership, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    35,500.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    35,500.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    35,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.31 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    The Loewenbaum Residence Trust FBO Anna Loewenbaum
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,800.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,800.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,800.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.10 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    CUSIP No.
    19516R107


    1Names of Reporting Persons

    The Elizabeth Scott Loewenbaum 1992 Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,700.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,700.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.10 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Based on 11,454,512 ordinary shares of the Issuer issued and outstanding as of September 30, 2024 (which number was set forth in the Report of Foreign Private Issuer on Form 6-K filed by the Issuer with the SEC on November 27, 2024).


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CollPlant Biotechnologies Ltd.
    (b)Address of issuer's principal executive offices:

    4 Oppenheimer St, Weizmann Science Park, Rehovot, L3, 7670104
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the individuals and entities listed below, all of whom together are referred to herein as the "Reporting Persons". (i) George Walter Loewenbaum, an individual (ii) Lillian S. Loewenbaum, an individual (iii) Elizabeth Loewenbaum, an individual (iv) Lillian S. Loewenbaum Grantor Retained Annuity Trust I, a Texas trust, (v) Lillian S. Loewenbaum Grantor Retained Annuity Trust V, a Texas trust, (vi) Lillian S. Loewenbaum Grantor Retained Annuity Trust VI, a Texas trust, (vii) The Loewenbaum 1992 Trust, a Texas trust, (viii) The Waterproof Partnership, Ltd., a Texas partnership, (ix) The Loewenbaum Residence Trust FBO Anna Loewenbaum, a Texas trust, and (x) The Elizabeth Scott Loewenbaum 1992 Trust, a Texas trust.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each Reporting Person is 1000 Westbank Dr, Ste #2A, Austin, TX 78746.
    (c)Citizenship:

    See Item 4 of each cover page.
    (d)Title of class of securities:

    Ordinary Shares, par value NIS 1.5 per share
    (e)CUSIP No.:

    19516R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 of each cover page.
    (b)Percent of class:

    See Item 11 of each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 of each cover page.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 of each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 of each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 of each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    George Walter Loewenbaum
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum
    Date:01/28/2025
     
    Lillian S. Loewenbaum
     
    Signature:/s/ Lillian S. Loewenbaum
    Name/Title:Lillian S. Loewenbaum
    Date:01/28/2025
     
    Elizabeth S. Loewenbaum
     
    Signature:/s/ Elizabeth Loewenbaum
    Name/Title:Elizabeth Loewenbaum
    Date:01/28/2025
     
    Lillian S. Loewenbaum Grantor Retained Annuity Trust I
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    Lillian S. Loewenbaum Grantor Retained Annuity Trust V
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    Lillian S. Loewenbaum Grantor Retained Annuity Trust VI
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    The Loewenbaum 1992 Trust
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    Signature:/s/ Lillian S. Loewenbaum
    Name/Title:Lillian S. Loewenbaum, Trustee
    Date:01/28/2025
     
    The Waterproof Partnership, Ltd.
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, General Partner
    Date:01/28/2025
     
    Signature:/s/ Lillian S. Loewenbaum
    Name/Title:Lillian S. Loewenbaum, General Partner
    Date:01/28/2025
     
    The Loewenbaum Residence Trust FBO Anna Loewenbaum
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    Signature:/s/ Lillian S. Loewenbaum
    Name/Title:Lillian S. Loewenbaum, Trustee
    Date:01/28/2025
     
    The Elizabeth Scott Loewenbaum 1992 Trust
     
    Signature:/s/ George Walter Loewenbaum
    Name/Title:George Walter Loewenbaum, Trustee
    Date:01/28/2025
     
    Signature:/s/ Lillian S. Loewenbaum
    Name/Title:Lillian S. Loewenbaum, Trustee
    Date:01/28/2025

    Comments accompanying signature:  EXHIBIT INDEX Exhibit Exhibit A: Joint Filing Agreement.
    Get the next $CLGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLGN

    DatePrice TargetRatingAnalyst
    2/17/2023$22.75Buy
    Alliance Global Partners
    More analyst ratings

    $CLGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

      Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is

      5/23/22 8:00:00 AM ET
      $CFRX
      $CLGN
      $ENLV
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors

      REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v

      8/19/21 8:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      2/13/24 4:01:04 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      1/25/24 3:27:05 PM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by CollPlant Biotechnologies Ltd (Amendment)

      SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)

      7/24/23 6:27:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on CollPlant with a new price target

      Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75

      2/17/23 8:30:35 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on CollPlant Biotechnologies with a new price target

      HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously

      2/9/21 6:08:53 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    Financials

    Live finance-specific insights

    See more

    $CLGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

      REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

      5/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corp

      3/26/25 8:00:00 AM ET
      $CLGN
      $SSYS
      Industrial Specialties
      Health Care
      Computer peripheral equipment
      Technology
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

      Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel, March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets. The Company will then host a conference call, the audio of which will be webcast to discuss its financial results and corporate updates on Wednesday, March 26th at 10:

      3/19/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

      REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise pr

      5/30/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

      - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  REHOVOT, Israel, May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained discip

      5/28/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

      REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombina

      5/14/25 7:00:00 AM ET
      $CLGN
      Industrial Specialties
      Health Care

    $CLGN
    SEC Filings

    See more
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/30/25 7:09:50 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      5/28/25 7:43:52 AM ET
      $CLGN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by CollPlant Biotechnologies Ltd

      6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)

      4/15/25 8:14:46 AM ET
      $CLGN
      Industrial Specialties
      Health Care